Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First Line Gefitinib Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) by the FDG-PET Metabolic Response

NCT01510990 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT01510990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01510990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First Line Gefitinib Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) by the FDG-PET Metabolic Response
Lead sponsor
Asan Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2012
Completion date
November 30, 2015
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer